Skip to main content
    B

    Boston Scientific Corp (BSX)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NYSE

    $43.70
    -0.64 (-1.44%)

    Market Cap: $64.27B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Boston Scientific Corp (BSX) Financials: Revenue, Profit and Cash Flow

    Updated Oct 28, 2026. Financial statements from company filings, amounts in US dollars.

    Boston Scientific reported revenue of $20.07B for the fiscal year ended Dec 31, 2025, up 19.9% from the year before. That year, net income was $2.89B with a net margin of 14.4%, operating cash flow was $4.53B and free cash flow was $3.66B. The quarter ended Sep 30, 2026 had revenue of $5.14B and net income of $580.00M.

    Revenue and Margins

    The operating margin was 18.0% in the fiscal year ended Dec 2025, the highest of the 10 years shown. Over the 9 years to Dec 2025, revenue grew from $8.39B, a compound annual rate of 10.2%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$20.07B+19.9%69.0%18.0%14.4%
    Dec 2024$16.75B+17.6%68.6%15.5%11.0%
    Dec 2023$14.24B+12.3%69.5%16.5%11.2%
    Dec 2022$12.68B+6.7%68.8%13.0%5.5%
    Dec 2021$11.89B+19.9%68.8%10.1%8.8%
    Dec 2020$9.91B-7.7%65.0%-0.8%-0.8%
    Dec 2019$10.73B+9.3%71.0%14.1%43.8%
    Dec 2018$9.82B+8.6%71.4%15.3%17.0%
    Dec 2017$9.05B+7.9%71.3%14.2%1.1%
    Dec 2016$8.39BN/A71.1%5.3%4.1%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, net income rose 56.2% from the year before. In the quarter ended Sep 2026, net income fell 23.2% from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$20.07B$16.75B$14.24B$12.68B$11.89B$9.91B$10.73B$9.82B$9.05B$8.39B
    Cost of revenue$6.22B$5.26B$4.34B$3.96B$3.71B$3.46B$3.12B$2.81B$2.59B$2.42B
    Gross profit$13.85B$11.49B$9.90B$8.73B$8.18B$6.45B$7.62B$7.01B$6.46B$5.96B
    Research and development$2.05B$1.61B$1.41B$1.32B$1.20B$1.14B$1.17B$1.11B$997.00M$920.00M
    Operating income$3.61B$2.60B$2.34B$1.65B$1.20B-$80.00M$1.52B$1.51B$1.28B$447.00M
    Net income$2.89B$1.85B$1.59B$698.00M$1.04B-$82.00M$4.70B$1.67B$104.00M$347.00M
    EBITDA$5.23B$3.91B$3.45B$2.78B$2.54B$1.46B$2.22B$2.56B$2.02B$1.25B
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$5.14B$5.44B$5.20B$5.29B$5.07B$5.06B$4.66B$4.56B$4.21B$4.12B$3.86B$3.73B
    Gross profit$3.43B$3.85B$3.61B$3.68B$3.54B$3.42B$3.21B$3.10B$2.90B$2.85B$2.65B$2.58B
    Operating income$828.00M$1.18B$1.10B$825.00M$1.05B$819.00M$921.00M$675.00M$733.00M$520.00M$675.00M$584.00M
    Net income$580.00M$905.00M$1.34B$670.00M$755.00M$795.00M$672.00M$563.00M$468.00M$322.00M$493.00M$504.00M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, total debt of $11.44B exceeded cash and equivalents by $9.47B.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$43.67B$39.40B$35.14B$32.47B$32.23B$30.78B$30.57B$21.00B$19.04B$18.10B
    Current assets$8.79B$6.92B$6.51B$5.76B$6.32B$6.69B$4.70B$4.00B$3.82B$3.24B
    Cash and equivalents$1.97B$414.00M$865.00M$928.00M$1.93B$1.73B$217.00M$146.00M$188.00M$196.00M
    Total liabilities$19.20B$17.39B$15.61B$14.90B$15.61B$15.45B$16.69B$12.27B$12.03B$11.36B
    Short-term debt$299.00M$1.78B$531.00M$20.00M$261.00M$13.00M$1.42B$2.25B$1.80B$64.00M
    Long-term debt$11.14B$8.97B$8.57B$8.91B$8.80B$9.13B$8.59B$4.80B$3.81B$5.42B
    Shareholder equity$24.23B$21.77B$19.28B$17.57B$16.62B$15.34B$13.88B$8.73B$7.01B$6.73B
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$45.46B$45.22B$44.35B$43.67B$42.71B$41.56B$40.14B$39.40B$38.08B$37.11B$36.67B$35.14B
    Total liabilities$19.59B$20.04B$18.25B$19.20B$19.08B$18.91B$17.69B$17.39B$17.12B$16.50B$16.50B$15.61B
    Cash and equivalents$609.00M$539.00M$1.45B$2.04B$1.27B$534.00M$725.00M$414.00M$2.50B$2.91B$2.33B$865.00M
    Shareholder equity$25.63B$24.93B$25.86B$24.23B$23.39B$22.42B$22.21B$21.77B$20.71B$20.37B$19.93B$19.28B
    Last 12 quarters

    Cash Flow

    In the fiscal year ended Dec 2025, free cash flow was 80.8% of operating cash flow.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow$4.53B$3.44B$2.50B$1.53B$1.87B$1.51B$1.84B$310.00M$1.43B$1.18B
    Capital expenditures$876.00M$790.00M$711.00M$588.00M$554.00M$376.00M$461.00M$316.00M$319.00M$376.00M
    Free cash flow$3.66B$2.65B$1.79B$938.00M$1.32B$1.13B$1.38B-$6.00M$1.11B$806.00M
    Dividends paidN/A$0$28.00M$55.00M$55.00M$28.00M$0$0$28.00M$0
    Share repurchasesN/AN/AN/AN/AN/A$535.00M$0$0N/AN/A
    Investing cash flow-$2.64B-$5.69B-$2.57B-$2.01B-$1.60B-$411.00M-$5.04B-$1.92B-$1.01B-$887.00M
    Financing cash flow-$395.00M$1.81B$5.00M-$548.00M-$95.00M$293.00M$2.97B$1.43B$110.00M-$206.00M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow$1.05B$1.47B$348.00M$1.36B$1.34B$1.29B$541.00M$1.46B$1.00B$813.00M$164.00M$957.00M
    Capital expenditures$180.00M$195.00M$177.00M$351.00M$181.00M$157.00M$187.00M$277.00M$179.00M$155.00M$179.00M$267.00M
    Free cash flow$868.00M$1.28B$171.00M$1.01B$1.16B$1.13B$354.00M$1.18B$823.00M$658.00M-$15.00M$690.00M
    Last 12 quarters

    Frequently Asked Questions About BSX

    What is Boston Scientific's annual revenue?

    Boston Scientific reported revenue of $20.07B for the fiscal year ended Dec 31, 2025.

    How fast is Boston Scientific's revenue growing?

    Revenue was up 19.9% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 16.5%.

    Is Boston Scientific profitable?

    Yes. Boston Scientific reported net income of $2.89B for the fiscal year ended Dec 31, 2025, with a net margin of 14.4%.

    How much free cash flow does BSX generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of $4.53B minus capital expenditures of $876.00M produced free cash flow of $3.66B.

    How much debt does Boston Scientific have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $11.14B, short-term debt of $299.00M and cash and equivalents of $1.97B.